Appendix 4C and Quarterly Activity Report 30 June 2026

Summary by 6ix AI

The report highlights positive free cash flow for the quarter and the full year, with significant revenue growth attributed to Penthrox in both Australia and Europe. Additionally, the company has received regulatory approval for the paediatric use of Penthrox in the UK and EU, expanding its market potential. The cash balance at the end of the quarter was reported to be substantial, supporting ongoing operations and strategic initiatives.

Written by 6ix AI from the company’s filing. How 6ix writes summaries